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ABSTRACT 
Background 
Tests of tumour treatment time effect in patients prescribed post-operative radiotherapy 
for early breast cancer have focussed on time to start of radiotherapy rather than overall 
treatment time. The START randomised trials of radiotherapy fractionation provide an 
opportunity to directly estimate the effect of treatment acceleration. 
Methods 
Between 1986 and 2002, a total of 5861 women with early breast cancer were recruited 
into the UK START pilot (START-P), START-A and START-B randomised trials. START-
P and START-A tested 13 fractions of 3.0-3.3 Gy against 25 fractions of 2.0 Gy with a 
fixed treatment duration of 5 weeks for all schedules; START-B tested 15 fractions of 2.67 
Gy in 3 weeks against 25 fractions of 2.0 Gy over 5 weeks. Estimates of the effect of 
length of treatment for local-regional relapse and for a measure of late normal tissue 
effects (change in photographic breast appearance, for patients following breast 
conserving surgery) were obtained from Cox proportional hazards regression analyses 
stratified according to trial. 
Results 
At a median follow-up of 10 years, 444/5831 (7.6%) patients with data available had a 
local-regional relapse, and 1135/3185 (35.6%) had mild or marked change in 
photographic breast appearance by 5 years. Adjusting for prognostic factors, the estimate 
of the overall treatment time effect for local-regional relapse was 0.60 Gy/day (95%CI 
0.10 to 1.18 Gy/day, p=0.02), and 0.14 Gy/day (95%CI -0.09 to 0.34 Gy/day, p=0.29) for 
change in photographic breast appearance. 
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Conclusions 
Combined analysis of the START trials generates the hypothesis that overall treatment 
time is a significant determinant of local cancer control after adjuvant whole breast 
radiotherapy, with approximately 0.6 Gy per day ‘wasted’ in compensating for tumour cell 
proliferation.  
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INTRODUCTION 
Convincing evidence for a time-factor in radiotherapy exists for squamous carcinomas of 
the head and neck, where at least 0.6 Gy per day of treatment is required to compensate 
for tumour cell repopulation between fractions, including week-end breaks [1-5]. There are 
no comparable tests of treatment time in patients prescribed adjuvant radiotherapy 
following primary surgery for early breast cancer, where studies are limited to exploring 
the impact of treatment delay. Such sources include randomised trials comparing 
concomitant versus sequential adjuvant chemo-radiotherapy, representing a difference in 
time from surgery to radiotherapy of 4 months or so (reviewed in [6]). One of three studies 
reported better local control after concomitant chemo-radiotherapy, but an excess of late 
telangiectasia after concomitant therapy suggests a time-independent effect may have 
contributed to the difference in outcome [7]. The only randomised trial testing sequence of 
chemotherapy and radiotherapy directly had limited power (N=244) and reported no 
dependency of long-term local relapse in irradiated breast on whether CMF chemotherapy 
or breast radiotherapy was given first [8]. The evidence for an impact of delay is not all 
negative, since a large retrospective cohort analysis of the Surveillance, Epidemiology, 
and End Results (SEER) Program studied >18000 US women with early stage breast 
cancer aged >65 years treated 1991-2002 with breast conserving surgery, radiotherapy 
but no chemotherapy, and this study reported a continuous association between the 
interval from breast conserving surgery to radiotherapy and local recurrence risk [8-11]. 
 
Two randomised trials testing hypofractionation in early breast cancer, the Ontario and 
START-B trials of adjuvant whole breast radiotherapy, tested schedules delivered in 
shorter overall treatment time than the international standard of 50 Gy in 25 fractions over 
5 weeks [12, 13]. The START-P and START-A trials were designed to generate direct 
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estimates of α/β for tumour control and normal tissue effects while controlling overall 
treatment time, and can be used to adjust for differences in dose-fractionation between 
randomised groups in the START-B trial [12, 14, 15]. We have used all three START trials 
to generate a crude estimate of the effect of overall treatment time for tumour (local 
control) [15, 16, 17]. Since there would be no expected time factor for late adverse effects 
in schedules extending over 6-8 weeks, the photographic assessments of change in 
photographic breast appearance were also tested using the same methods as for tumour 
control, to act as a control [18]. 
 
MATERIALS AND METHODS 
Design, methods and results of the START pilot, A and B trials have been published 
elsewhere [12, 14, 15, 16, 17]. The START pilot (N=1410) and START A trials (N=2236) 
tested 3.0-3.3 Gy against 2.0 Gy fractions with overall treatment time fixed at 5 weeks, 
allowing direct estimates of the fractionation sensitivity of breast cancer. A meta-analysis 
of the START pilot and START A trials with those of the START B trial (N=2215) testing 
15 fractions of 2.67 Gy in 3 weeks against 25 fractions of 2.0 Gy over 5 weeks allowed 
estimation of the possible change in treatment effect for a 3-week versus a 5-week 
schedule for local-regional relapse and for the normal tissue effects endpoint of any 
change in photographic breast appearance. Only patients who had breast conserving 
surgery were eligible for the photographic assessments, which scored change in breast 
appearance annually up to 5 years and then at 10 years in START-P and at 2 and 5 years 
in START A and B compared with a post-surgery baseline photograph taken prior to start 
of radiotherapy treatment [19]. 
Statistical methods 
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Cox proportional hazards (PH) regression analyses of time to local-regional relapse and 
time to any change in photographic breast appearance were stratified by trial to allow for 
differences in case mix among trials. Crude estimates of the proliferation effect for each 
endpoint was obtained from separate Cox PH regression models including terms for total 
dose (βDose), total dose x dose per fraction (βDxd) and a dummy variable for treatment time 
(βtime), where 0 represents 5 weeks and 1 represents 3 weeks. The actual length of 
radiotherapy treatment for each patient according to reported start and finish dates was 
not used in the analysis, although very few had major delays [16, 17]. Parameter 
estimates obtained from the Cox PH regression were then used in the following formula to 
estimate the dose recovered per day due to proliferation (in 2.0 Gy equivalent fractions), 
assuming a 14-day time difference between the 2 schedules in START trial B:         
 
        
           
 
Non-parametric bootstrap resampling was used to obtain bias-corrected 95% confidence 
intervals (CI) of the Dprolif estimate. Known prognostic factors were included in the Cox PH 
regression models: age, type of primary surgery, radiotherapy to axilla or supraclavicular 
fossa, tumour bed boost, adjuvant chemotherapy, tamoxifen, pathological tumour size for 
local-regional relapse; age, adjuvant chemotherapy, tamoxifen, radiotherapy to axilla or 
supraclavicular fossa, breast size and surgical deficit for any change in photographic 
breast appearance. Tumour grade and nodal status were not included in the model for 
local-regional relapse due to the number of patients for which these variables were 
unknown.  
 
RESULTS 
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Post-randomisation data were available for 5831 of the 5861 patients entered into the 
START pilot, START A and B trials, of whom 444 were reported to have had a local-
regional relapse (402/4730 (8.5%) for all 5-week schedules combined and 42/1101 (3.8%) 
for the 3-week schedule); median follow-up was 10 years overall. Scores for any change 
in photographic breast appearance at 2 and/or 5 years were available for 3185 patients, 
of whom 1135 were scored as mild or marked change. Patient clinical and treatment 
characteristics for the analysis dataset are shown in Table 1 for the 5-week schedules 
versus the 3-week schedule. There were some differences due to varying case mix 
between the three START trials. The crude (unadjusted) estimate of Dprolif for local-
regional relapse was 0.65 Gy/day (95%CI 0.12 to 1.66 Gy/day). Adjusting for prognostic 
factors for local-regional relapse (type of primary surgery, radiotherapy to axilla or 
supraclavicular fossa, tumour bed boost, adjuvant chemotherapy, tamoxifen, pathological 
tumour size) in 5613 patients with data available for all variables in the Cox PH regression 
model gave an adjusted estimate of Dprolif for local-regional relapse of 0.60 Gy/day 
(95%CI 0.10 to 1.18 Gy/day) (Table 2). Thus, the effect of overall treatment time on local-
regional control is statistically significant (p=0.02). Corresponding estimates of Dprolif for 
any change in photographic breast appearance were 0.17 Gy/day (95%CI -0.10 to 0.36 
Gy/day) for the crude estimate, and 0.14 Gy/day (95%CI -0.09 to 0.34 Gy/day) adjusted 
for age, radiotherapy to axilla or supraclavicular fossa, adjuvant chemotherapy, tamoxifen, 
breast size and surgical deficit (Table 2). The effect of overall treatment time on change in 
photographic breast appearance is not statistically significant (p=0.29 for the adjusted 
estimate). 
 
DISCUSSION 
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This is a hypothesis-generating study suggesting that treatment time influences local 
outcome of adjuvant radiotherapy in breast cancer. The literature referred to in the 
Introduction yields conflicting results, most commonly based on the analysis of treatment 
delay. Our investigation was prompted by a suggestion of lower local-regional relapse 
rates after 40 Gy in 15 fractions over 3 weeks compared with 50 Gy in 25 fractions over 5 
weeks reported in START-B (estimate of absolute difference –1·2%, 95% CI –2·6% to 
1·0%). The START-B trial was powered for non-inferiority and the observed effect was not 
statistically significant, but the 95% confidence interval was more suggestive of lower 
local-regional relapse rates (by up to 2.6%) than of a higher rate for the 3-week schedule. 
This prompted further examination on the grounds that the local-regional relapse rate was 
expected to be higher after 40 Gy in 15 fractions than after 50 Gy in 25 fractions, for the 
following reason. The α/β point estimate of 3.5 Gy for local-regional tumour control in the 
START-P and START-A trials applied to the START-B 40Gy in 15 fractions schedule 
generates an equivalent total dose delivered in 2.0 Gy fractions (EQD2Gy) that is closer 
to 45 Gy than 50 Gy, assuming no impact of treatment time. The slope of the dose-
response for local control rates >90% is very shallow, so a large difference in local control 
could not be expected, even for an EQD2Gy 5 Gy lower than the Control group receives. 
Assuming the slope of the dose-response curve at the 95% level of local control is 
described by a gamma value 0.1-0.2 (ten times shallower than at 50% levels of local 
control), the expected absolute inferiority in local control would be 1 to 2%. So, the 
observed 4.3% 10-year local-regional relapse rate after 40 Gy in 15 fractions is about 2.2 
to 3.2 percentage points lower than predicted, assuming no time effect. This is how the 
observed non-inferiority of tumour control in START B raises the possibility of a treatment 
time effect on tumour control, which our results estimate to be 0.6 Gy per day (95%CI 
0.10 to 1.18 Gy per day).  
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The main strength of this study is that it is based on data collected systematically and 
prospectively in randomised trials that pre-specified and quality-assured the delivery of 
radiotherapy and ensured high compliance with collection of post-treatment outcome data. 
The main weakness is that the estimate for a treatment time effect is based on a single 
trial (START-B), given that the duration of treatment was 5 weeks for all schedules in the 
START-P and START-A trials. In addition, although randomisation is the most effective 
way of balancing prognostic variables between treatment groups, small imbalances are 
inevitable, even in a trial of >2000 patients. Whether or not the above factors apply here, 
it is noteworthy that the Ontario trial testing 42.5 Gy in 16 fractions of 2.7 Gy in 3.2 weeks 
whole breast radiotherapy against 50 Gy in 25 fractions did not detect any differences in 
long-term outcome between schedules, either in terms of local tumour control (absolute 
difference, 1.5 percentage points; 95% CI −6.9 to 9.8) or breast cosmesis (absolute 
difference, 0.5 percentage points; 95% CI −2.5 to 3.5) [13]. It took only 19 days to deliver 
15 fractions in START-B when treatment started on a Monday and was uninterrupted, but 
on average, most patients started on another week-day resulting in a treatment duration 
of 21 days compared with the 22 days needed to deliver 16 fractions in the Ontario trial. In 
other words, the difference in treatment time between these two trials could be closer to 1 
day than 3 days. The different outcomes in the START B and Ontario trials could possibly 
be due to differences in the tumour characteristics of the populations tested in the two 
trials, particularly tumour grade, or simply be a factor of the imprecision in the tumour 
control estimates. 
If a treatment time effect for breast cancer is real and of the magnitude estimated in this 
analysis, the implications are significant. For patient populations suffering local relapse 
risks >10% following conventionally fractionated radiotherapy, the absolute gains in local 
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control from adopting a 3-week schedule are likely to be clinically worthwhile, even 
without considering the lower adverse event rates (e.g. HR 0.8, 95% CI 0.67-0.96 for 
breast shrinkage) associated with this regimen in the START-B trial [12]. The implications 
for tumour bed boost dose regimens would be that synchronous/concomitant boost would 
be more effective than sequential boost techniques; this is the hypothesis tested in the UK 
IMPORT HIGH and RTOG 1005 trials. For patient populations experiencing local relapse 
risks <<10% after conventional fractionation, the main benefit would be the reduced rate 
of late adverse events reported after 40 Gy in 15 fractions, as described above [12]. 
The final point of discussion relates to the adjusted estimate of 0.14 Gy/day (95%CI -0.09 
to 0.34 Gy/day) as the time factor for late change in photographic breast appearance. 
Assuming this is a real effect (it is not statistically significantly different from zero, 
p=0.286), the difference between the estimates for local control and for late effects still 
means that a therapeutic gain can be achieved from shortening overall treatment time. In 
fact, testing the one-sided hypothesis that the treatment time effect for subclinical breast 
cancer exceeds that for late effects (measured by photographic breast appearance in this 
analysis) yields a statistically significant p-value of p=0.03. If there is a small, effect of 
overall treatment time it could be explained by the distinction between a ‘true’ late effect, 
which might not be expected to show a time effect, from a ‘consequential’ late effect that 
is a result (direct consequence) of healing by secondary intention of a severe early effect, 
usually moist desquamation in inframammary and other skin folds [20]. Telangiectasia is 
the most visible manifestation in the irradiated breast, but severe cases can be 
accompanied by subcutaneous induration and atrophy impacting on breast appearance. 
Numbers of events were too small to allow testing of association between a time factor 
and breast size as a surrogate for moist desquamation risk in the START-B trial. In the 
existing literature, a time factor for telangiectasia has been reported by Turesson, 
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attributed to slow repair rather than repopulation [21]. More recently, two large 
randomised trials of radiotherapy in head and neck cancer testing 60 Gy in 30 fractions 
delivered in 5 or in 6 weeks reported no significant time factor for late adverse effects 
despite significantly higher rates of both early adverse effects and local tumour control [1, 
2]. In conclusion, we consider the time factor for late effects in START-B to represent a 
reasonable negative control for our analysis. 
 
Conclusions 
A meta-analysis of the START trials generates the hypothesis that overall treatment time 
is a significant determinant of local cancer control after adjuvant whole breast 
radiotherapy, with approximately 0.6 Gy per day ‘wasted’ in compensating for tumour cell 
proliferation. Independent replication is needed before this observation can be used in 
support of accelerated schedules of hypofractionated radiotherapy in breast cancer.  
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Table 1: Characteristics of the 5831 patients included in the analyses for the 5-week schedules 
from all 3 START trials combined and the 3-week schedule from START trial B 
 5-week 
schedules 
N=4730 (%)+ 
3-week 
schedule 
N=1101 (%)+ 
Total 
N=5831 (%)+ 
Age (years) 
Mean (SD)  
[range] 
 
56.3 (10.4)  
[23.3-86.8] 
 
57.8 (9.5)  
[30.9-82.9] 
 
56.6 (10.2)  
[23.3-86.8] 
Pathological tumour size 
(cm) 
Mean (SD) 
 
 
2.2 (1.6) 
 
 
1.8 (1.0) 
 
 
2.1 (1.5)   
Tumour grade 
1 
2 
3 
Unknown 
 
898 (23.8) 
1853 (49.1) 
1020 (27.0) 
959 
 
309 (28.6) 
527 (48.7) 
246 (22.7) 
19 
 
1207 (24.9) 
2380 (49.0) 
1266 (26.1) 
978 
Nodal status 
Negative 
Positive 
Unknown 
 
2924 (71.7) 
1152 (28.3) 
654 
 
797 (75.1) 
264 (24.9) 
40 
 
3721 (72.4) 
1416 (27.6) 
694 
Type of primary surgery 
Breast conserving surgery 
Mastectomy 
 
4310 (91.1) 
420 (8.9) 
 
1009 (91.6) 
92 (8.4) 
 
5319 (91.2) 
512 (8.8) 
Tumour bed radiotherapy 
boost 
No 
Yes 
Unknown 
 
 
2089 (44.4) 
2618 (55.6) 
23 
 
 
652 (59.5) 
444 (40.5) 
5 
 
 
2741 (47.2) 
3062 (52.8) 
28 
Radiotherapy to axilla or 
supraclavicular fossa 
No 
Yes 
Unknown 
 
 
4022 (85.4) 
686 (14.6) 
21 
 
 
1015 (92.6) 
81 (7.4) 
5 
 
 
5037 (86.8) 
767 (13.2) 
26 
Adjuvant chemotherapy 
No 
Yes 
 
3469 (73.6) 
1245 (26.4) 
 
864 (78.9) 
231 (21.1) 
 
4333 (74.6) 
1476 (25.4) 
Table 1
Unknown 16 6 22 
Adjuvant tamoxifen 
No 
Yes 
Unknown 
 
928 (19.7) 
3786 (80.3) 
16 
 
135 (12.3) 
960 (87.7) 
6 
 
1063 (18.3) 
4746 (81.7) 
22 
Breast size from baseline 
photograph* 
Small 
Medium 
Large 
 
 
344/2847 (12.1) 
2068/2847 (72.6) 
435/2847 (15.3) 
 
 
37/454 (8.1) 
344/454 (75.8) 
73/454 (16.1) 
 
 
381/3301 (11.5) 
2412/3301 (73.1) 
508/3301 (15.4) 
Surgical deficit from 
baseline photograph* 
Small 
Medium 
Large 
Unknown 
 
 
1701/2838 (59.9) 
909/2838 (32.0) 
228/2838 (8.0) 
9 
 
 
247/454 (54.4) 
162/454 (35.7) 
45/454 (9.9) 
0 
 
 
1948/3296 (59.1) 
1071/3296 (32.5) 
273/3296 (8.3) 
9 
 
+ %s calculated excluding unknowns 
* Baseline photographs available for 3301 of the 3185 patients who were in the 
photographic assessments sub-studies of the trials 
 
Table 2: Crude and adjusted bootstrap estimates of the proliferation parameter for 
local-regional relapse and change in photographic breast appearance (dose 
recovered per day in 2.0 Gy equivalent fractions) 
 
 Crude estimate (95%CI), 
Gy/day 
Adjusted estimate 
(95%CI),Gy/day 
Local-regional relapse 0.65 (0.12 to 1.66) 0.60 (0.10 to 1.18)1 
Any change in photographic 
breast appearance3 
0.17 (-0.10 to 0.36) 0.14 (-0.09 to 0.34)2 
 
1 Adjusted for age, type of primary surgery, radiotherapy to axilla or supraclavicular 
fossa, tumour bed boost, adjuvant chemotherapy, tamoxifen, pathological tumour 
size 
2 Adjusted for age, radiotherapy to axilla or supraclavicular fossa, adjuvant 
chemotherapy, tamoxifen, breast size, surgical deficit 
3 Any change in photographic breast appearance includes mild or marked change 
(compared with pre-radiotherapy baseline) 
 
Table 2
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